Oncology
Geoffrey Shapiro, MD PHD
Senior Vice President, Developmental Therapeutics; Clinical Director, Center for DNA Damage and Repair; Professor of Medicine, Harvard Medical School; Institute Physician, Dana-Farber Cancer Institute
Geoffrey Shapiro is a leading developmental oncologist specializing in early-phase clinical trials and targeted cancer therapeutics. At Dana-Farber Cancer Institute, he directs the Early Drug Development Center and serves as Clinical Director of the Center for DNA Damage and Repair, overseeing pioneering research in cell-cycle and DNA repair inhibitor therapeutics. His clinical practice encompasses solid tumors with particular expertise in thoracic cancers, gastrointestinal malignancies, and BRC
35+
Years in Practice
Credentials
Board Certifications
- Medical Oncology (ABIM)
Education & Training
- Cornell University (Weill Medical College) — Ph.D., 1987
- Cornell University (Weill Medical College) — M.D., 1988
- Beth Israel Hospital, Boston — Residency, Internal Medicine; Chief Medical Resident
- Dana-Farber Cancer Institute — Fellowship, Medical Oncology
Peer Recognition
- Castle Connolly — Top Doctor
2017-2026 (10 years)
Clinical Focus
Subspecialties
Conditions & Treatments
Practice Details
Hospital Affiliations
- Dana-Farber Cancer Institute
- Harvard Medical School
Languages
English
Experience
35+ years in practice